BEIGF (BeOne Medicines) Cyclically Adjusted FCF per Share: $-0.84 (As of Mar. 2026)


BEIGF BeOne Medicines Ltd BEIGF
61 GF Score
Price $21.95
GF Value $29.85
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BeOne Medicines Cyclically Adjusted FCF per Share?

BeOne Medicines BEIGF 61 Cyclically Adjusted FCF per Share is $-0.84 as of Mar. 2026. GuruFocus rates BEIGF with a GF Score™ of 61/100 and a GF Value™ of $29.85 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BeOne Medicines's adjusted free cash flow per share for the three months ended in Mar. 2026 was $0.107. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.84 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-12), BeOne Medicines's current stock price is $21.946. BeOne Medicines's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-0.84. BeOne Medicines's Cyclically Adjusted Price-to-FCF of today is .


BeOne Medicines  (OTCPK:BEIGF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BeOne Medicines Cyclically Adjusted FCF per Share Related Terms


BeOne Medicines Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Cyclically Adjusted FCF per Share Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.88 -0.89

BeOne Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.89 -0.76 -0.52 -0.89 -0.84

BEIGF vs MRNA, RPRX, ROIV: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, BeOne Medicines's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeOne Medicines Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Cyclically Adjusted Price-to-FCF falls into.


BEIGF
61GF Score
BeOne Medicines Ltd BEIGF
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BeOne Medicines's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.107/108.0600*108.0600
=0.107

Current CPI (Mar. 2026) = 108.0600.

BeOne Medicines Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.058 100.088 -0.063
201609 -0.072 99.604 -0.078
201612 -0.074 99.380 -0.080
201703 -0.083 100.040 -0.090
201706 -0.127 100.285 -0.137
201709 -0.020 100.254 -0.022
201712 0.127 100.213 0.137
201803 -0.185 100.836 -0.198
201806 -0.183 101.435 -0.195
201809 -0.215 101.246 -0.229
201812 -0.359 100.906 -0.384
201903 -0.288 101.571 -0.306
201906 -0.113 102.044 -0.120
201909 -0.379 101.396 -0.404
201912 -0.384 101.063 -0.411
202003 -0.404 101.048 -0.432
202006 -0.293 100.743 -0.314
202009 -0.367 100.585 -0.394
202012 -0.328 100.241 -0.354
202103 0.059 100.800 0.063
202106 -0.384 101.352 -0.409
202109 -0.467 101.533 -0.497
202112 -0.539 101.776 -0.572
202203 -0.268 103.205 -0.281
202206 -0.322 104.783 -0.332
202209 -0.513 104.835 -0.529
202212 -0.362 104.666 -0.374
202303 -0.509 106.245 -0.518
202306 -0.305 106.576 -0.309
202309 -0.187 106.570 -0.190
202312 -0.287 106.461 -0.291
202403 -0.370 107.355 -0.372
202406 -0.151 107.991 -0.151
202409 0.040 107.468 0.040
202412 -0.012 107.128 -0.012
202503 -0.050 107.722 -0.050
202506 0.137 108.075 0.137
202509 0.238 107.710 0.239
202512 0.253 107.200 0.255
202603 0.107 108.060 0.107

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.84 mean?
BeOne Medicines (BEIGF) has a Cyclically Adjusted FCF per Share of $-0.84 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' Cyclically Adjusted FCF per Share too high?
BeOne Medicines' current Cyclically Adjusted FCF per Share is $-0.84. Overall, BeOne Medicines has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Cyclically Adjusted FCF per Share compare to MRNA and RPRX?
BeOne Medicines' Cyclically Adjusted FCF per Share of $-0.84 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Cyclically Adjusted FCF per Share is $-0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (BEIGF) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.85, compared to a current price of $21.95 — trading 26.5% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $-0.84. BeOne Medicines' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For BeOne Medicines (BEIGF), the current Cyclically Adjusted FCF per Share is $-0.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (BEIGF) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $21.95 is trading 26.5% below its estimated GF Value™ of $29.85. GuruFocus considers BeOne Medicines to be Modestly Undervalued.

Key valuation signals for BEIGF:

  • Cyclically Adjusted FCF per Share: $-0.84
  • GF Value™: $29.85 vs. price of $21.95 (26.5% below fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the BEIGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
61GF Score

Get the complete analysis for BEIGF

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.95
Price
$29.85
GF Value